Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Travecta Therapeutics

Request full access

CNS drug delivery platform crossing blood-brain barrier

Philadelphia, United StatesFounded 2017Biotech & Life Sciences

About Travecta Therapeutics

Travecta Therapeutics is a biopharmaceutical company that has developed a novel drug delivery platform, mVECTA™, to transport therapeutics across the blood-brain barrier (BBB) and blood-retinal barrier. The company's technology is built on the scientific discoveries of its founder, Dr. David Silver, a professor at Duke-NUS Medical School, who identified the MFSD2a transporter protein's natural mechanism for carrying lipids to the brain. This platform allows the company to conjugate existing or new small molecules to lipid scaffolds, enabling their transport into the central nervous system (CNS) to treat previously inaccessible targets.

The company was founded in 2017 by Dr. David Silver, Dr. Mahmood Ahmed, and the SPRIM Ventures team, including Michael Shleifer and Laurent Benissan. Dr. Silver's foundational research, published in 2014, revealed how the Mfsd2a protein transports essential fatty acids into the brain, a discovery that addresses a major challenge in medicine, as the BBB typically prevents about 98% of small-molecule drugs from entering. Travecta's business model focuses on leveraging this intellectual property, licensed from Duke-NUS, to create a proprietary pipeline of therapies and collaborate with large pharmaceutical companies. The company operates in the biopharmaceutical market, with offices in Singapore and Princeton, New Jersey, focusing on CNS disorders.

Travecta's lead product candidate, TVT-004, is a non-opioid drug targeting pain. The company's pipeline also includes programs in neuro-oncology, neuro-inflammation, neurodegeneration, anxiety, multiple sclerosis, and epilepsy. By making drugs permeable to the BBB, the mVECTA™ platform aims to repurpose ineffective drug candidates and develop new treatments for a wide range of neurological and ocular diseases. The company secured $27 million in an oversubscribed Series A funding round led by TKS1, a venture fund partnership between SPRIM and Tikehau Capital, to advance its pipeline, with plans to move its lead compound into clinical trials.

Source: Dealroom company data

At a glance

Status
Operational
Employees
6
Open positions
None listed
Dealroom signal
51.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC May 2020 $15M $60M TKS1 ↗
SPINOUT✓Other financing Jan 2017 $0 — Duke-NUS Graduate Medical School Singapore —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Travecta Therapeutics website traffic

Latest recorded traffic for Travecta Therapeutics is 220 monthly website visits. Travecta Therapeutics's team grew 0% over the past year.

Latest monthly visits220 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Travecta Therapeutics in the Philadelphia ecosystem

Live from Dealroom

The Travecta Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • TKS1

Other known investors1 additional known investor

  • Duke-NUS Graduate Medical School Singapore
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Philadelphia HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Travecta Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Travecta Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.